Matthew Tunis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Matthew Tunis has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Ashleigh R. Tuite
Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
7 shared publications - Gebremedhin Beedemariam Gebretekle
Public Health Agency of Canada
6 shared publications - Alison E. Simmons
Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
5 shared publications Kelsey Young
5 shared publications- Raphael Ximenes
Public Health Agency of Canada
5 shared publications Adrienne Stevens
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Springer Nature in Canadian Journal of Public Health
Vaccination as cost-stabilizing health infrastructure: A Canadian perspective
As Canada contends with rising healthcare costs and health system strain, vaccination programs stand out as stabilizing health infrastructure. Vaccination can reduce the burden of avoidable illness and dampen volatility arising from seasonal disease surges and outbreaks. Together, these effects can preserve clinical and public health capacity, improve fiscal predictability, and support health system resilience. These system-level benefits are generally not fully captured by conventional cost-utility analyses. Drawing on Canadian evidence, we outline how vaccination programs stabilize healthcare use and spending, and how a stabilization lens complements conventional economic evaluation. Recognizing vaccines as cost-stabilizing infrastructure may influence how vaccination programs are prioritized, budgeted, and evaluated in health system planning.
- 16 June 2026
- Published by Springer Nature in Canadian Journal of Public Health
Open AccessVaccination as cost-stabilizing health infrastructure: A Canadian perspective
As Canada contends with rising healthcare costs and health system strain, vaccination programs stand out as stabilizing health infrastructure. Vaccination can reduce the burden of avoidable illness and dampen volatility arising from seasonal disease surges and outbreaks. Together, these effects can preserve clinical and public health capacity, improve fiscal predictability, and support health system resilience. These system-level benefits are generally not fully captured by conventional cost-utility analyses. Drawing on Canadian evidence, we outline how vaccination programs stabilize healthcare use and spending, and how a stabilization lens complements conventional economic evaluation. Recognizing vaccines as cost-stabilizing infrastructure may influence how vaccination programs are prioritized, budgeted, and evaluated in health system planning.
- 26 March 2026
- Published by Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada in Relevé des maladies transmissibles au Canada
- Vol. 52 (3) , 59-70
Le Comité consultatif national de l’immunisation (CCNI) du Canada en 2025 : célébration de 60 ans de service, d’une décennie de changement et d’un avenir dynamique
- 26 March 2026
- Published by Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada in Relevé des maladies transmissibles au Canada
- Vol. 52 (3) , 59-70
Le Comité consultatif national de l’immunisation (CCNI) du Canada en 2025 : célébration de 60 ans de service, d’une décennie de changement et d’un avenir dynamique
- Open Access
- 26 March 2026
- Published by Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada in Canada Communicable Disease Report
- Vol. 52 (3) , 56-66
Canada’s National Advisory Committee on Immunization (NACI) in 2025: Celebrating 60 years of service, a decade of change, and a dynamic future ahead
Canada’s National Advisory Committee on Immunization (NACI) marked its 60th anniversary in 2024, representing six decades of reliable advice supporting Canada’s immunization programs. Over the past decade, NACI expanded its mandate to include ethics, equity, feasibility, acceptability, and economic considerations, while adapting its methods to align with international standards and responding to urgent public health needs such as the COVID-19 pandemic. Enhanced collaboration with provinces, territories, Indigenous partners, and global peers has strengthened both the relevance and reach of NACI guidance. With an expanding vaccine landscape, NACI continues to evolve as a trusted national and global resource supporting equitable, evidence-informed immunization policy and practice in Canada.
- 26 March 2026
- Published by Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada in Canada Communicable Disease Report
- Vol. 52 (3) , 56-66
Open AccessCanada’s National Advisory Committee on Immunization (NACI) in 2025: Celebrating 60 years of service, a decade of change, and a dynamic future ahead
Canada’s National Advisory Committee on Immunization (NACI) marked its 60th anniversary in 2024, representing six decades of reliable advice supporting Canada’s immunization programs. Over the past decade, NACI expanded its mandate to include ethics, equity, feasibility, acceptability, and economic considerations, while adapting its methods to align with international standards and responding to urgent public health needs such as the COVID-19 pandemic. Enhanced collaboration with provinces, territories, Indigenous partners, and global peers has strengthened both the relevance and reach of NACI guidance. With an expanding vaccine landscape, NACI continues to evolve as a trusted national and global resource supporting equitable, evidence-informed immunization policy and practice in Canada.
- Open Access
Evaluating respiratory syncytial virus immunization strategies for infants in Canada: a cost-utility analysis
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and hospitalizations among infants in Canada. New long-acting monoclonal antibodies (mAbs) and vaccines administered during pregnancy have expanded prevention options, yet the most cost-effective immunization program remains uncertain. Methods: We updated a Canadian cost-utility model to evaluate seven seasonal RSV prevention strategies over one year (with a lifetime horizon for mortality impacts), from health system and societal perspectives. Strategies included RSVpreF vaccination in late pregnancy; targeted or universal infant mAb programs using nirsevimab or clesrovimab; and combination programs in which infants could receive protection from either RSVpreF or mAbs. Sequential incremental cost-effectiveness ratios (ICERs) were estimated in 2024 Canadian dollars per quality-adjusted life year (QALY), using a $50,000/QALY threshold. The primary analysis used immunization product list prices. Findings: The most cost-effective strategy was a seasonal combination program: RSVpreF vaccination for pregnancies due during RSV season with mAb for infants at high risk (0/7 to 36 6/7 weeks' gestation) or high-risk with catch-up. Expanding mAb to unimmunized non-high-risk infants born in-season increased the ICER to $132,131/QALY. Universal infant protection (mAb alone or combined with RSVpreF in pregnancy) was not cost-effective across analyses. RSVpreF alone was dominated. Results were most sensitive to product prices, target populations, age at administration, and RSV burden. Conclusions: A seasonal combination program with RSVpreF for in-season deliveries and mAb for infants at high-risk offers the best value for money for protecting Canadian infants from RSV disease. Broader infant immunization programs may be cost-effective with substantial price reductions or in regions with higher disease burden and healthcare costs.
Open AccessEvaluating respiratory syncytial virus immunization strategies for infants in Canada: a cost-utility analysis
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and hospitalizations among infants in Canada. New long-acting monoclonal antibodies (mAbs) and vaccines administered during pregnancy have expanded prevention options, yet the most cost-effective immunization program remains uncertain. Methods: We updated a Canadian cost-utility model to evaluate seven seasonal RSV prevention strategies over one year (with a lifetime horizon for mortality impacts), from health system and societal perspectives. Strategies included RSVpreF vaccination in late pregnancy; targeted or universal infant mAb programs using nirsevimab or clesrovimab; and combination programs in which infants could receive protection from either RSVpreF or mAbs. Sequential incremental cost-effectiveness ratios (ICERs) were estimated in 2024 Canadian dollars per quality-adjusted life year (QALY), using a $50,000/QALY threshold. The primary analysis used immunization product list prices. Findings: The most cost-effective strategy was a seasonal combination program: RSVpreF vaccination for pregnancies due during RSV season with mAb for infants at high risk (0/7 to 36 6/7 weeks' gestation) or high-risk with catch-up. Expanding mAb to unimmunized non-high-risk infants born in-season increased the ICER to $132,131/QALY. Universal infant protection (mAb alone or combined with RSVpreF in pregnancy) was not cost-effective across analyses. RSVpreF alone was dominated. Results were most sensitive to product prices, target populations, age at administration, and RSV burden. Conclusions: A seasonal combination program with RSVpreF for in-season deliveries and mAb for infants at high-risk offers the best value for money for protecting Canadian infants from RSV disease. Broader infant immunization programs may be cost-effective with substantial price reductions or in regions with higher disease burden and healthcare costs.
- Open Access
Cost-utility analysis of current COVID-19 vaccination program recommendations in Canada
Background: As COVID-19 becomes established as an endemic disease with widespread population immunity, there is uncertainty about the economic benefit of ongoing COVID-19 vaccination programs. We assessed the cost-effectiveness of a COVID-19 vaccination program similar to current Canadian recommendations, modelled as annual vaccination for people aged less than 65 years with chronic medical conditions and biannual vaccination for adults aged 65 years and older. Methods: Using a static individual-based model of medically attended COVID-19 in a population of 1 million people, we estimated costs (in 2023 Canadian dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We used health system and societal perspectives and a 1.5% discount rate. Parameters were based on recent COVID-19 epidemiology, vaccine characteristics, and costs. Results: Between July 2024 and September 2025, a program similar to current Canadian recommendations was estimated to avert 3.1% (95% credible interval (CrI): 3.0 to 3.2%) of outpatient cases, 8.8% (95% CrI: 7.3 to 10.4%) of inpatient cases, 3.6% (95% CrI: 2.8 to 4.3%) of PCC cases, and 9.4% (95% CrI: 5.6 to 13.8%) of deaths compared to no vaccination. The number needed to vaccinate to prevent one hospitalization and one death was 1,121 (95% CrI: 941 to 1,357) and 8,656 (95% CrI: 5,848 to 14,915), respectively. For the health system perspective, the program would cost an additional $4.695 million but result in 221.17 QALYs gained, leading to an ICER of $21,227 per QALY compared to no vaccination. Vaccine price influenced cost-effectiveness, with higher prices reducing the likelihood the program met common cost-effectiveness thresholds. Conclusions: A program similar to current COVID-19 recommendations in Canada is likely effective and cost-effective compared to no vaccination. However, unlike some other research studies, alternate vaccination strategies that may offer better value for money were not evaluated.
Open AccessCost-utility analysis of current COVID-19 vaccination program recommendations in Canada
Background: As COVID-19 becomes established as an endemic disease with widespread population immunity, there is uncertainty about the economic benefit of ongoing COVID-19 vaccination programs. We assessed the cost-effectiveness of a COVID-19 vaccination program similar to current Canadian recommendations, modelled as annual vaccination for people aged less than 65 years with chronic medical conditions and biannual vaccination for adults aged 65 years and older. Methods: Using a static individual-based model of medically attended COVID-19 in a population of 1 million people, we estimated costs (in 2023 Canadian dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We used health system and societal perspectives and a 1.5% discount rate. Parameters were based on recent COVID-19 epidemiology, vaccine characteristics, and costs. Results: Between July 2024 and September 2025, a program similar to current Canadian recommendations was estimated to avert 3.1% (95% credible interval (CrI): 3.0 to 3.2%) of outpatient cases, 8.8% (95% CrI: 7.3 to 10.4%) of inpatient cases, 3.6% (95% CrI: 2.8 to 4.3%) of PCC cases, and 9.4% (95% CrI: 5.6 to 13.8%) of deaths compared to no vaccination. The number needed to vaccinate to prevent one hospitalization and one death was 1,121 (95% CrI: 941 to 1,357) and 8,656 (95% CrI: 5,848 to 14,915), respectively. For the health system perspective, the program would cost an additional $4.695 million but result in 221.17 QALYs gained, leading to an ICER of $21,227 per QALY compared to no vaccination. Vaccine price influenced cost-effectiveness, with higher prices reducing the likelihood the program met common cost-effectiveness thresholds. Conclusions: A program similar to current COVID-19 recommendations in Canada is likely effective and cost-effective compared to no vaccination. However, unlike some other research studies, alternate vaccination strategies that may offer better value for money were not evaluated.
- Open Access
Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2 circulation in Canada
Background: With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for ongoing COVID-19 vaccination programs are increasingly important. We assessed the cost-effectiveness of COVID-19 vaccination programs, where eligibility is defined by combinations of age and chronic medical conditions, including a strategy similar to current Canadian recommendations, from the health system and societal perspectives. Methods: We used a static, individual-based probabilistic model simulating medically attended COVID-19 in a population of 1 million people followed over a 15-month time period to estimate costs in 2023 Canadian dollars, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs), discounted at 1.5%. COVID-19 epidemiology, vaccine characteristics, and costs were based on the most recently available data. Results: Annual vaccination for adults aged 65 years and older consistently emerged as a cost-effective intervention, with ICERs less than $50,000 per QALY compared to no vaccination for a range of model assumptions. Adding a second dose for adults aged 65 years and older or expanding programs to include vaccination for younger age groups, including those at higher risk of COVID-19 due to chronic medical conditions, generally resulted in ICERs of greater than $50,000 per QALY. Shifting timing of vaccination programs to better align with periods of high COVID-19 case occurrence could result in biannual vaccination for those aged 65 and older being a cost-effective strategy. Conclusions: COVID-19 vaccination programs may be cost-effective when focused on groups at higher risk of disease. Optimal timing of vaccination could improve the cost-effectiveness of various strategies.
Open AccessCost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2 circulation in Canada
Background: With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for ongoing COVID-19 vaccination programs are increasingly important. We assessed the cost-effectiveness of COVID-19 vaccination programs, where eligibility is defined by combinations of age and chronic medical conditions, including a strategy similar to current Canadian recommendations, from the health system and societal perspectives. Methods: We used a static, individual-based probabilistic model simulating medically attended COVID-19 in a population of 1 million people followed over a 15-month time period to estimate costs in 2023 Canadian dollars, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs), discounted at 1.5%. COVID-19 epidemiology, vaccine characteristics, and costs were based on the most recently available data. Results: Annual vaccination for adults aged 65 years and older consistently emerged as a cost-effective intervention, with ICERs less than $50,000 per QALY compared to no vaccination for a range of model assumptions. Adding a second dose for adults aged 65 years and older or expanding programs to include vaccination for younger age groups, including those at higher risk of COVID-19 due to chronic medical conditions, generally resulted in ICERs of greater than $50,000 per QALY. Shifting timing of vaccination programs to better align with periods of high COVID-19 case occurrence could result in biannual vaccination for those aged 65 and older being a cost-effective strategy. Conclusions: COVID-19 vaccination programs may be cost-effective when focused on groups at higher risk of disease. Optimal timing of vaccination could improve the cost-effectiveness of various strategies.
- Open Access
- 25 October 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100575
COVID-19 vaccine evidence monitoring assisted by artificial Intelligence: An emergency system implemented by the Public Health Agency of Canada to capture and describe the trajectory of evolving pandemic vaccine literature
- 25 October 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100575
Open AccessCOVID-19 vaccine evidence monitoring assisted by artificial Intelligence: An emergency system implemented by the Public Health Agency of Canada to capture and describe the trajectory of evolving pandemic vaccine literature
- Open Access
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Background: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD). Objective: To assess the cost-effectiveness of PCV21 compared to current Canadian vaccination recommendations for adults of different age and risk groups. Methods: We used a static cohort model to estimate lifetime incremental cost-effectiveness ratios (ICERs), in 2023 Canadian dollars per quality-adjusted life year (QALY), discounted at 1.5%, in population cohorts aged 33 (midpoint of the 18-49 year age group), 50, and 65 years from the health system and societal perspectives. The primary analysis used 2022 serotype distributions for IPD cases. Additional analyses incorporated indirect effects from pediatric vaccination and used IPD serotype distributions from 2015-2019, to explore the impact of changes over time observed in some age groups. Results: For population groups currently recommended to receive PCV20 in Canada (65 years and older, 50-64 years with additional risk factors for IPD, or 18-49 years with immunocompromising conditions), PCV21 was cost-effective at a $50,000 per QALY threshold and dominated PCV20 in most scenarios when PCV21 serotypes were more prevalent. When PCV20 serotypes were equally or more prevalent than PCV21 serotypes, results were more sensitive to assumptions about indirect effects and serotype replacement. For groups not currently recommended a conjugate vaccine (50-64 years without additional IPD risk factors and 18-49 years with chronic medical conditions or unhoused populations), use of a higher-valency conjugate vaccine was a cost-effective intervention compared to no vaccination, with the optimal vaccine dependent on the proportion of IPD attributable to PCV20 and PCV21 serotypes in the population of interest. Results were sensitive to vaccine price in most scenarios. Interpretation: The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.
Open AccessCost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Background: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD). Objective: To assess the cost-effectiveness of PCV21 compared to current Canadian vaccination recommendations for adults of different age and risk groups. Methods: We used a static cohort model to estimate lifetime incremental cost-effectiveness ratios (ICERs), in 2023 Canadian dollars per quality-adjusted life year (QALY), discounted at 1.5%, in population cohorts aged 33 (midpoint of the 18-49 year age group), 50, and 65 years from the health system and societal perspectives. The primary analysis used 2022 serotype distributions for IPD cases. Additional analyses incorporated indirect effects from pediatric vaccination and used IPD serotype distributions from 2015-2019, to explore the impact of changes over time observed in some age groups. Results: For population groups currently recommended to receive PCV20 in Canada (65 years and older, 50-64 years with additional risk factors for IPD, or 18-49 years with immunocompromising conditions), PCV21 was cost-effective at a $50,000 per QALY threshold and dominated PCV20 in most scenarios when PCV21 serotypes were more prevalent. When PCV20 serotypes were equally or more prevalent than PCV21 serotypes, results were more sensitive to assumptions about indirect effects and serotype replacement. For groups not currently recommended a conjugate vaccine (50-64 years without additional IPD risk factors and 18-49 years with chronic medical conditions or unhoused populations), use of a higher-valency conjugate vaccine was a cost-effective intervention compared to no vaccination, with the optimal vaccine dependent on the proportion of IPD attributable to PCV20 and PCV21 serotypes in the population of interest. Results were sensitive to vaccine price in most scenarios. Interpretation: The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.
- Open Access
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
Background Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease. Objective Assess the cost-effectiveness of RSVpreF and nirsevimab programs in preventing RSV disease in infants, compared to a palivizumab program. Methods We used a static cohort model of a Canadian birth cohort during their first RSV season to estimate sequential incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjusted life year (QALY) for nine strategies implemented over a one-year time period, from the health system and societal perspectives. Sensitivity and scenario analyses were conducted to explore the impact of uncertainties on the results. Results All-infants nirsevimab programs averted more RSV-related outcomes than year-round RSVpreF programs, with the most RSV cases averted in seasonal nirsevimab programs. Assuming list prices for these immunizing agents, all-infants nirsevimab and year-round RSVpreF programs were never cost-effective, with ICERs far exceeding commonly used cost-effectiveness thresholds. Seasonal nirsevimab with catch-up was cost-effective if prioritized for infants at moderate/high-risk (ICER <$28,000 per QALY) or those living in settings with higher RSV burden and healthcare costs (ICER of $5,700 per QALY). Using a $50,000 per QALY threshold, an all-infants nirsevimab program could be optimal if nirsevimab is priced at <$110-190 per dose. A year-round RSVpreF for all pregnant women/pregnant people plus nirsevimab for infants at high-risk was optimal if nirsevimab is priced at >$110-190 and RSVpreF priced at <$60-125. Interpretation Prophylactic interventions can substantially reduce RSV disease in infants, and targeted nirsevimab programs are the most cost-effective option at current product prices.
Open AccessCost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
Background Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease. Objective Assess the cost-effectiveness of RSVpreF and nirsevimab programs in preventing RSV disease in infants, compared to a palivizumab program. Methods We used a static cohort model of a Canadian birth cohort during their first RSV season to estimate sequential incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjusted life year (QALY) for nine strategies implemented over a one-year time period, from the health system and societal perspectives. Sensitivity and scenario analyses were conducted to explore the impact of uncertainties on the results. Results All-infants nirsevimab programs averted more RSV-related outcomes than year-round RSVpreF programs, with the most RSV cases averted in seasonal nirsevimab programs. Assuming list prices for these immunizing agents, all-infants nirsevimab and year-round RSVpreF programs were never cost-effective, with ICERs far exceeding commonly used cost-effectiveness thresholds. Seasonal nirsevimab with catch-up was cost-effective if prioritized for infants at moderate/high-risk (ICER <$28,000 per QALY) or those living in settings with higher RSV burden and healthcare costs (ICER of $5,700 per QALY). Using a $50,000 per QALY threshold, an all-infants nirsevimab program could be optimal if nirsevimab is priced at <$110-190 per dose. A year-round RSVpreF for all pregnant women/pregnant people plus nirsevimab for infants at high-risk was optimal if nirsevimab is priced at >$110-190 and RSVpreF priced at <$60-125. Interpretation Prophylactic interventions can substantially reduce RSV disease in infants, and targeted nirsevimab programs are the most cost-effective option at current product prices.
- Open Access
Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis
Background: Vaccines against respiratory syncytial virus (RSV) have the potential to reduce disease burden and costs in Canadians, but the cost-effectiveness of RSV vaccination programs for older adults is unknown. We evaluated the cost-effectiveness of different adult age cutoffs for RSV vaccination programs, with or without a focus on people with higher disease risk due to chronic medical conditions (CMCs). Methods: We developed a static individual-based model of medically-attended RSV disease to evaluate the cost-utility of alternate age-, medical risk-, and age-plus medical risk-based vaccination policies. The model followed a multi-age cohort of 100,000 people aged 50 years and older over a three-year period. Vaccine characteristics were based on RSV vaccines authorized in Canada as of March 2024. We calculated incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjust life year (QALY) from the health system and societal perspectives, discounted at 1.5%. Results: Although all vaccination strategies averted medically-attended RSV disease, strategies focused on adults with CMCs were more likely to be cost-effective than age-based strategies. A program focused on vaccinating adults aged 70 years and older with one or more CMCs was optimal for a cost-effectiveness threshold of $50,000 per QALY. Results were sensitive to assumptions about vaccine price, but approaches based on medical risk remained optimal compared to age-based strategies even when vaccine prices were low. Findings were robust to a range of alternate assumptions. Interpretation: Based on available data, RSV vaccination programs in some groups of older Canadians with underlying medical conditions are expected to be cost-effective.
Open AccessRespiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis
Background: Vaccines against respiratory syncytial virus (RSV) have the potential to reduce disease burden and costs in Canadians, but the cost-effectiveness of RSV vaccination programs for older adults is unknown. We evaluated the cost-effectiveness of different adult age cutoffs for RSV vaccination programs, with or without a focus on people with higher disease risk due to chronic medical conditions (CMCs). Methods: We developed a static individual-based model of medically-attended RSV disease to evaluate the cost-utility of alternate age-, medical risk-, and age-plus medical risk-based vaccination policies. The model followed a multi-age cohort of 100,000 people aged 50 years and older over a three-year period. Vaccine characteristics were based on RSV vaccines authorized in Canada as of March 2024. We calculated incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjust life year (QALY) from the health system and societal perspectives, discounted at 1.5%. Results: Although all vaccination strategies averted medically-attended RSV disease, strategies focused on adults with CMCs were more likely to be cost-effective than age-based strategies. A program focused on vaccinating adults aged 70 years and older with one or more CMCs was optimal for a cost-effectiveness threshold of $50,000 per QALY. Results were sensitive to assumptions about vaccine price, but approaches based on medical risk remained optimal compared to age-based strategies even when vaccine prices were low. Findings were robust to a range of alternate assumptions. Interpretation: Based on available data, RSV vaccination programs in some groups of older Canadians with underlying medical conditions are expected to be cost-effective.